Biological mesh is a safe and effective method of abdominal wall reconstruction in cytoreductive surgery for peritoneal malignancy

被引:7
作者
Tzivanakis, A. [1 ]
Dayal, S. P. [1 ]
Arnold, S. J. [1 ]
Mohamed, F. [1 ]
Cecil, T. D. [1 ]
Venkatasubramaniam, A. K. [1 ]
Moran, B. J. [1 ]
机构
[1] Basingstoke & North Hampshire Hosp, Peritoneal Malignancy Inst, Basingstoke RG24 9NN, Hants, England
来源
BJS OPEN | 2018年 / 2卷 / 06期
关键词
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; PSEUDOMYXOMA PERITONEI; INCISIONAL HERNIA; COMPONENTS SEPARATION; MORBIDITY; DISSEMINATION; MANAGEMENT; CLOSURE; RISK;
D O I
10.1002/bjs5.93
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Patients with peritoneal malignancy often have multiple laparotomies before referral for cytoreductive surgery (CRS). Some have substantial abdominal wall herniation and tumour infiltration of abdominal incisions. CRS involves complete macroscopic tumour removal and hyperthermic intraperitoneal chemotherapy (HIPEC). Abdominal wall reconstruction is problematic in these patients. The aim of this study was to establish immediate and long-term outcomes of abdominal wall reconstruction with biological mesh in a single centre. Methods: A dedicated peritoneal malignancy database was searched for all patients who had biological mesh abdominal wall reconstruction between 2004 and 2015. Short- and long-term outcomes were reviewed. All patients had annual abdominal CT as routine peritoneal malignancy follow-up. Results: Some 33 patients (22 women) with a mean age of 53.4 (range 19-82) years underwent abdominal wall reconstruction with biological mesh. The majority (23) had CRS for pseudomyxoma (19 low grade), six for colorectal peritoneal metastasis and four for appendiceal adenocarcinoma; 18 had undergone CRS and HIPEC previously. Twenty-five of the 33 patients had abdominal wall tumour involvement and eight had concurrent hernias. The mean duration of surgery was 486 (range 120-795) min and the mean mesh size used was 345 (50-654) cm(2). Ten patients developed wound infections and four had a seroma. Two developed early enterocutaneous fistulas. Mean follow-up was 48 months. Five patients developed an incisional hernia. Four died from progressive malignancy. A further 15 patients had disease recurrence, but only one had isolated abdominal wall recurrence. Conclusion: Biological mesh was safe and effective for abdominal wall reconstruction in peritoneal malignancy. Postoperative wound infections were frequent but nevertheless incisional hernia rates were low with no instances of mesh-related bowel erosion or fistulation.
引用
收藏
页码:464 / 469
页数:6
相关论文
共 50 条
  • [1] Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis
    Wong, Joelle F. S.
    Tan, Grace H. C.
    Wang, Weining
    Soo, K. C.
    Teo, Melissa C. C.
    WORLD JOURNAL OF SURGERY, 2015, 39 (06) : 1578 - 1583
  • [2] Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?
    Strong, Erin A.
    Livingston, Austin
    Gracz, Maciej
    Peltier, Wendy
    Tsai, Susan
    Christians, Kathleen
    Gamblin, T. Clark
    Kersting, Karen
    Clarke, Callisia N.
    JOURNAL OF SURGICAL RESEARCH, 2022, 278 : 31 - 38
  • [3] Indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients with peritoneal malignancy
    Kitai, Toshiyuki
    Yamanaka, Kenya
    Miyauchi, Yuya
    Kawashima, Masahiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 519 - 525
  • [4] Reinforcement of the Abdominal Wall following Breast Reconstruction with Abdominal Flaps: A Comparison of Synthetic and Biological Mesh
    Patel, Ketan M.
    Shuck, John
    Hung, Rex
    Hannan, Lindsay
    Nahabedian, Maurice Y.
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2014, 133 (03) : 700 - 707
  • [5] An update of peritonectomy procedures used in cytoreductive surgery for peritoneal malignancy
    Mercier, Frederic
    Mohamed, Faheez
    Cazauran, Jean-Baptiste
    Kepenekian, Vahan
    Vaudoyer, Delphine
    Cotte, Eddy
    Glehen, Olivier
    Passot, Guillaume
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2019, 36 (01) : 744 - 752
  • [6] Abdominal Wall Morbidity Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Struller, F.
    Koenigsrainer, I.
    Horvath, P.
    Koenigsrainer, A.
    Beckert, S.
    SCANDINAVIAN JOURNAL OF SURGERY, 2017, 106 (04) : 294 - 298
  • [7] Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis
    Joelle F. S. Wong
    Grace H. C. Tan
    Weining Wang
    K. C. Soo
    Melissa C. C. Teo
    World Journal of Surgery, 2015, 39 : 1578 - 1583
  • [8] Parenteral nutrition after cytoreductive surgery for peritoneal malignancy: Should it be administered routinely?
    Khan, Ayman
    Beaumont, Anna
    Laing, Erin
    Guerra, Glen
    Jain, Anshini
    Warrier, Satish
    Heriot, Alexander
    CLINICAL NUTRITION ESPEN, 2023, 57 : 487 - 493
  • [9] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly is Safe and Effective
    Laks, Shachar
    Bilik, Alona
    Schtrechman, Gal
    Adileh, Mohammad
    Mor, Eyal
    Boursi, Ben
    Halpern, Naama
    Margalit, Ofer
    Shacham-Shmueli, Einat
    Nissan, Aviram
    Ben-Yaacov, Almog
    JOURNAL OF SURGICAL RESEARCH, 2022, 279 : 739 - 747
  • [10] Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy
    Sutton, P. A.
    O'Dwyer, S. T.
    Barriuso, J.
    Aziz, O.
    Selvasekar, C. R.
    Renehan, A. G.
    Wilson, M. S.
    SURGICAL ONCOLOGY-OXFORD, 2021, 38